# Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

Study · id `cardio:ct-nct06674460` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06674460](<https://clinicaltrials.gov/study/NCT06674460>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06674460

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT06674460. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-01 (actual); primary completion 2027-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT06674460, source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)
- Started: 2025-08-01 (actual) (ClinicalTrials.gov record NCT06674460, source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT06674460, source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)
- Completion: 2028-10-01 (anticipated) (ClinicalTrials.gov record NCT06674460, source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06674460, source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06674460-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
- Acronym: TASTE-SVD
- Condition: Cerebral Small Vessel Disease
- Condition: Ischemic Stroke
- Intervention (Drug): Edaravone Dexborneol Sublingual Tablets
- Intervention (Drug): Placebo
- Lead sponsor: Peking Union Medical College Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)

## Provenance

Content hash: 081b854ddb700f503e0afe6a56343e07fa622eb2c19beb8cf0501990106dcfd1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
